GZR4

Phase 3Small molecule

GGan and Lee Pharmaceuticals, USA

GZR4 is one of 96 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Hepatic ImpairmentActive, not recruiting

MPARecruiting

Type 2 Diabetes MellitusPhase 3

Active, not recruiting

Hepatic ImpairmentPhase 1

Active, not recruiting

MPAPhase 1

Recruiting

Competition

Competitive Landscape

145 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 3

5 2

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 3

Retatrutide

Eli Lilly

Phase 3

1 4

GZR4

GGan and Lee Pharmaceuticals, USA

Phase 3

5 5

Elecoglipron

AstraZeneca

Phase 3

5 6

Ganagliflozin

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

1 7

Imeglimin

PPoxel SA

Phase 3

1 8

Dorzagliatin

HHua Medicine Limited

Adenocard

1 10

NOVOLIN R

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Type 2 Diabetes Mellitus

NCT07165223

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus5 trials

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT06767748·620 enrolled

A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin

Recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT07165223·300 enrolled

A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus

Completed·GGan and Lee Pharmaceuticals, USA·Phase 2·NCT06202079·179 enrolled

Show 2 more trials

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT06767735·580 enrolled

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT06767761·580 enrolled

Tics1 trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4

Completed·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT06548815·43 enrolled

Type 2 Diabetes1 trial

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes

Completed·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT06553248·36 enrolled

Overweight1 trial

A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects

Not yet recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT06974487·30 enrolled

MPA1 trial

Comparison Study of Insulin GZR4 With Insulin Degludec

Recruiting·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT07146347·14 enrolled

3 more indications

Hepatic Impairment1 trial

Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT07193147·36 enrolled

Renal Impairment1 trial

Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment

Completed·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT06547502·16 enrolled

Unspecified1 trial

A Study of GZR4 Injection at Different Injection Sites

Recruiting·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT06548906·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for GZR4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GZR4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GZR4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gan and Lee Pharmaceuticals, USA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGan and Lee Pharmaceuticals, USA

GZR4

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Type 2 Diabetes Mellitus5 trials

Tics1 trial

Type 2 Diabetes1 trial

Overweight1 trial

MPA1 trial

Hepatic Impairment1 trial

Renal Impairment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News